Lenalidomidă Alkaloid-Int

Lenalidomide, the active ingredient in Lenalidomidă Alkaloid-Int, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It treats multiple myeloma and myelodysplastic syndromes in adult patients, including those with relapsed or refractory disease, and is administered under specialist supervision.

GNH USA supplies Lenalidomidă Alkaloid-Int as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring quality‑assured product delivery and regulatory compliance. The company adheres to Good Distribution Practice and provides comprehensive support for regulatory documentation, customs clearance and temperature‑controlled logistics where required.

Lenalidomide is employed in hematologic oncology to target malignant plasma cells and dysplastic bone‑marrow clones, improving disease outcomes.

Multiple myeloma: used in combination regimens to prolong progression‑free survival and overall survival in patients with newly diagnosed or relapsed disease. Myelodysplastic syndromes (MDS) with del(5q): administered to reduce transfusion dependence and improve hematologic parameters in adult patients with this cytogenetic abnormality. Multiple myeloma maintenance: continued after induction and consolidation to maintain remission and delay disease progression in patients who have responded to prior therapy.

Lenalidomide is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduction in neutrophil count that may increase susceptibility to bacterial infections. - Fatigue: persistent tiredness that can affect daily activities and quality of life. - Diarrhea: frequent loose stools that may lead to dehydration if severe. - Nausea: sensation of queasiness often accompanied by vomiting.

Serious or Rare Side Effects: - Thromboembolic events: formation of blood clots such as deep‑vein thrombosis or pulmonary embolism, requiring immediate medical attention. - Severe neutropenia or leukopenia: profound decrease in white‑blood‑cell counts, markedly raising infection risk. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: rare, life‑threatening skin reactions characterized by blistering and detachment.

When using Lenalidomidă Alkaloid-Int, careful monitoring and risk mitigation are essential. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. - Assess thrombotic risk: evaluate patient history for clotting disorders and consider prophylactic anticoagulation. - Avoid pregnancy: women of childbearing potential must use effective contraception during treatment and for a defined period after cessation. - Adjust for renal impairment: dose may need modification in patients with reduced kidney function. - Review concomitant medications: check for drugs that may interact and affect safety. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding or altered anticoagulant effect. - Live vaccines: immunosuppression may diminish vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase lenalidomide plasma levels. - NSAIDs (e.g., ibuprofen): combined use can raise the chance of gastrointestinal toxicity. - Digoxin: potential for altered digoxin concentrations requiring level monitoring.